Longevity Investment Landscape: How VCs Are Betting On Aging

The longevity sector has emerged as one of the most compelling yet controversial investment frontiers, with venture capitalists placing significant bets on technologies and therapeutics aimed at extending healthspan and potentially lifespan. This investment landscape spans diverse approaches from cellular reprogramming and senolytic drugs to AI-driven drug discovery and preventive diagnostics, creating a complex ecosystem where scientific promise intersects with commercial viability questions and skepticism about timeline-to-impact.

Understanding how sophisticated investors are evaluating longevity opportunities reveals important insights about risk assessment, value creation timelines, and the criteria that separate credible science-backed ventures from speculative hype. As the sector matures beyond early enthusiasm, VCs are developing more refined frameworks for assessing longevity investments, balancing the sector's transformative potential against the scientific uncertainties, regulatory challenges, and extended development timelines that characterize this emerging field.

Join us to discuss:

• What investment thesis and evaluation criteria are VCs using to assess longevity opportunities, and how are these frameworks evolving as the sector matures?
• Which longevity subsectors and therapeutic approaches are attracting the strongest investor interest, and what factors are driving capital allocation decisions?
• How are investors managing the unique challenges of longevity investing, including extended timelines, regulatory uncertainty, and the balance between scientific credibility and commercial potential?